研究者
J-GLOBAL ID：201601010729843198
更新日: 2024年11月22日
小貫 律子
オヌキリツコ | Onuki Ritsuko
所属機関・部署：
職名：
研究員
その他の所属（所属・部署名・職名） (1件)：
研究分野 (2件)：
システムゲノム科学
, 統計科学
研究キーワード (1件)：
バイオインフォマティクス
論文 (12件)：
-
Ryu Okada, Hisanori Takenobu, Shunpei Satoh, Ryuichi P. Sugino, Ritsuko Onuki, Masayuki Haruta, Kyosuke Mukae, Atsuko Nakazawa, Jesmin Akter, Miki Ohira, et al. L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to Cells. 2024
-
HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, et al. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer. Anticancer Research. 2024. 44. 5. 1925-1930
-
Kiyohiro Ando, Ryo Kurashina, Noriko Motoi, Toshihiko Iizuka, Masaharu Inoue, Riko Maruyama, Kouki Mitani, Hisanori Takenobu, Masayuki Haruta, Ritsuko Onuki, et al. Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma. Biochemical and Biophysical Research Communications. 2023. 676. 165-170
-
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO, et al. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma. Cancer Diagnosis & Prognosis. 2023. 3. 2. 230-235
-
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, et al. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers. 2022. 14. 5522
もっと見る
MISC (1件)：
-
Koichi Ichimura, Motoo Nagane, Mamoru Kato, Yoshitaka Narita, Tomokazu Aoki, Shota Tanaka, Akitake Mukasa, Toshihiko Wakabayashi, Takeo Uzuka, Hideo Nakamura, et al. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS. NEURO-ONCOLOGY. 2019. 21. 12-13
講演・口頭発表等 (12件)：
-
Deep Learning for Mutation Detection in Comprehensive Genomic Profiling and its Evaluation
(1st Asia & Pacific Bioinformatics Joint Conference 2024 2024)
-
Development of Cancer Mutation Visualization Tools for Large Samples
(The 82nd Annual Meeting of the Japan Cancer Association 2023)
-
Informatics in Cancer Genome Research
(Informatics in Biology, Medicine and Pharmacology 2023 2023)
-
Deep Learning for Mutation Detection in Cancer Genome Medicine
(The 81st Annual Meeting of the Japanese Cancer Association 2022)
-
非Germinoma中枢神経系胚細胞腫瘍の単一核遺伝子発現解析
(日本脳神経医科学会 2021)
もっと見る
学位 (1件)：
前のページに戻る
